×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
After NASH flops, Conatus becomes Histogen via reverse merger
Fierce Biotech
After its Novartis-partnered nonalcoholic steatohepatitis (NASH) drug failed a third midphase trial, Conatus Pharma was in trouble.
52 months ago
In a Strategic Realignment, Conatus Pharma Merges with Histogen
BioSpace
The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.
52 months ago
Top 70+ startups in Hepatic Disorders Drugs
Tracxn
Globally there are 72 Hepatic Disorders Drugs companies which include top companies like Nimbus Therapeutics, Mirum Pharmaceuticals and...
2 months ago
Novo Nordisk's semaglutide misses the mark in NASH study
Fierce Pharma
In a phase 2 trial of Novo Nordisk's Type 2 diabetes drug Ozempic (semaglutide) against NASH, it was outdone by placebo by a significant...
23 months ago
Novartis buys two firms in pre-Christmas shopping spree
PMLiVE
Acquires eye disease specialist Encore Vision and NASH drug firm Conatus Pharma.
89 months ago
Conatus wields ax as Novartis-partnered NASH drug fails again
Fierce Biotech
A phase 2b trial of Conatus Pharmaceuticals' emricasan in nonalcoholic steatohepatitis (NASH) has.
59 months ago
PMC Buys Isochem’s Pharma Business
CHEManager
PMC Group France, a wholly owned subsidiary of US-based PMC Group International, has acquired the pharmaceuticals business of France's...
77 months ago
Non-Alcoholic Steatohepatitis (NASH) Market to Hit $21.47 Billions by 2025 | Current Trends and Indu
PharmiWeb.com
Non-alcoholic steatohepatitis (NASH) market was valued at $1179 million in 2017, and is expected to reach $21478 million by 2025,...
6 months ago
Premarket analyst action - healthcare (NASDAQ:NVAX)
Seeking Alpha
Novavax (NASDAQ:NVAX) initiated with Neutral rating by Seaport Global Securities.Seaport initiates coverage of the following with Buy...
79 months ago
Conatus and Novartis suffer another midphase NASH flop
Fierce Biotech
Conatus Pharmaceuticals' emricasan has failed another midphase clinical trial. The latest setback saw the Novartis-partnered liver disease...
62 months ago